Reported Earlier, Beam Therapeutics Sets 2026 Strategic Priorities, Aligns With U.S. FDA On Potential Accelerated Approval Pathway For BEAM-302, And Ends 2025 With Preliminary Estimated $1.25B Cash

Beam Therapeutics +1.82%

Beam Therapeutics

BEAM

24.66

+1.82%

  • Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints
  • U.S. Biologics Licensing Application (BLA) Submission for risto-cel (Previously Known as BEAM-101) Expected as Early as Year-End 2026
  • Expansion of Liver-targeted Genetic Disease Franchise Underway with New Program to be Announced in First Half of 2026
     
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.